Abstract
Few series describing the results of autologous bone marrow transplantation (ABMT) for the treatment of non-Hodgkin’s lymphoma report mature follow-up. We retrospectively reviewed 110 adults with NHL treated with ABMT from 1988 to 1993. Overall survival and relapse-free survival were 50% and 35%, respectively. Estimated median relapse-free survival was 16 months. There was no statistically significant difference in relapse-free or overall survival by low, intermediate, and high-grade histologies, as defined by the International Working Formulation. The most powerful negative prognostic variable was an elevated LDH at the time of transplant (relapse-free survival 17% vs 42% for those with a normal LDH). Forty-seven patients were in complete remission 2 years after transplant. Extended follow-up revealed that 100% of patients with high-grade histologies remained in complete remission, whereas patients with intermediate-grade and low-grade histologies remained at risk of relapse with longer follow-up. Of 22 patients with diffuse large cell lymphoma (LCL) or immunoblastic (IBL) histologies, eight of eight with IBL remain in continued remission, while four of 14 with LCL relapsed 24–48 months after ABMT. We conclude that patients with high-grade histologic subtypes of NHL who are in complete remission 2 years after ABMT are likely to be cured. However, patients with intermediate and low-grade histologic subtypes are at continued risk of relapse and require appropriate clinical surveillance for at least 48 months after ABMT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bolwell, B., Goormastic, M. & Andresen, S. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point. Bone Marrow Transplant 19, 443–448 (1997). https://doi.org/10.1038/sj.bmt.1700678
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700678
Keywords
This article is cited by
-
High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma
Bone Marrow Transplantation (2021)
-
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
Leukemia (2011)
-
Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma
Bone Marrow Transplantation (2003)
-
Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
Bone Marrow Transplantation (2003)
-
Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up
Bone Marrow Transplantation (2002)